SEARCH
Mast Therapeutics, Inc.
San Diego, CA 92130 United States
Phone
Fax
Research Sector Pharmaceutical
Summary Description Hematology and oncology-focused biopharmaceutical company with three clinical-stage product candidates.
Management Brian M. Culley, CEO; Santosh Vetticaden, CMO; Patrick Keran, President & Chief Operating Officer; Martin R. Emanuele, Senior Vice President, Development; Gregory D. Gorgas, Senior Vice President, Commercial; Brandi L. Roberts, CPA, Vice President, Finance Click here for Financial Data
Keywords: sickle cell disease, microvascular, hematology, oncology, shock, copolymer, chemotherapy, nonsmallcelllungcancer, lungcancer, breastcancer, solidtumor, cytoprotective, ischemia, acutelimbischemia
Updated: Mar. 04, 2015
Description
Mast Therapeutics, Inc. (NYSE MKT: MSTX) is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant Tech......view more
Products / Services
Mast's lead product candidate, MST-188 (formerly ANX-188) is a purified form of a nonionic, triblock copolymer (poloxamer 188). It binds to hydrophobic surfaces on damaged cells and improves membrane ......view more
Technology / Differentiation
MST-188 is an investigational agent, formulated using a purified form of poloxamer 188. Substantial research has demonstrated that poloxamer 188 has cytoprotective and hemorrheologic properties and in...view more
Status
- The company is currently recruiting patients with sickle cell disease to participate in EPIC, its phase 3 trial of MST-188. At the end of March, 2013, the European Commission designated MST-188 as a...view more